Inhibition of combined application of arsenic trioxide and cisplatin in the HSQ-89 cells

VernacularTitle:三氧化二砷与顺铂合用抗人口腔癌细胞株HSQ-89的实验研究
Author: Sui JIANG ; Yongkang YE ; Zhongwei CHEN ; Can PENG ; Chaoyang LUO
Publication Type:Journal Article
Keywords: Oral cancer; Arsenic trioxide; Cisplatin
From: The Journal of Practical Medicine 2014;(15):2371-2373
CountryChina
Language:Chinese
Abstract: Objective To discuss the anticancer role of arsenic trioxide (ATO) with cisplatin on human oral carcinoma HSQ-89 cells. Methods The human oral epidermoid HSQ-89 cells were chosen as the subjects. Different concentrations of ATO were added into Cisplatin(DDP)-treated cells. The inhibition rate of tumor cells was detected by MTT assay. Results Different concentrations of ATO (0,2.5,5,7.5,10,12.5 μmol/mL) were added into oral cancer HSQ-89 cells which have been treated with DDP (15 μg/mL). The inhibition rate of tumor cells were 26.9%, 67.5%, 73.0%, 88.5%, 90.4%, 98.7%respectively; The combined application of ATO with cisplatin could improve the inhibition rate of HSQ-89 cells in a dose-dependent relation. Conclusion The combined application of ATO and DDP can produce a synergistic action of inhibition on oral cancer cell.